Compare Crocs, Inc. (CROX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Sanofi SA — how do they compare? Crocs, Inc. trades at $116.22 (market cap $5.60B), while Sanofi SA trades at $40.14 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 17× Crocs, Inc.'s market cap, and Sanofi SA pays a 6.01% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Sanofi SA for 94 Days on average.
| CROX | SNY | |
|---|---|---|
Market Cap | $5.60B | $95.18B |
Volume | 1,026,773 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $52.34 |
52-Week Low | $73.39 | $39.51 |
Typical Hold Time | 96 Days | 94 Days |
Enterprise Value | $7.12B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $117.64, up 2.12% with recent earnings beats driving positive momentum. The stock shows bearish technical signals but maintains strong fundamentals including a 10.37 P/E ratio and 42.3% ROE. Recent management commentary highlights product innovation and HEYDUDE brand repositioning as growth catalysts. Cash flow trends show consistent operational strength despite recent net income volatility.
The outlook remains cautiously optimistic with analyst consensus targeting $136.78 (16% upside). Key risks include consumer discretionary spending sensitivity and execution challenges with brand diversification. The combination of attractive valuation, strong profitability metrics, and positive earnings surprises supports potential long-term appreciation despite near-term technical weakness.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
